fbpx
April 24, 2024

New cancer clinical trial: The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer

Published on: July 28, 2017 at 12:00PM
Conditions:   Carcinoma, Non-Small-Cell Lung;   Lung Cancer;   Non-Small Cell Lung Cancer
Interventions:   Drug: Decitabine (DAC);   Drug: Tetrahydrouridine (THU);   Drug: Pembrolizumab
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting – verified July 21, 2017
http://ift.tt/2uctiOZ

%d bloggers like this: